Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Buy rating on Alnylam Pharmaceuticals and raised the price target from $366 to $384.
November 01, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity has reaffirmed its Buy rating on Alnylam Pharmaceuticals and increased the price target from $366 to $384, indicating a positive outlook.
The reaffirmation of a Buy rating and an increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100